FDA reviews DNA-based colon cancer screening kits

March 24, 2014

The Food and Drug Administration is weighing the benefits and risks of two experimental colon cancer screening tests which use DNA from a patient's stool to detect dangerous tumors and growths.

FDA scientists have questions about the accuracy and the real-world impact of the kits, if they are approved. The agency posted its reviews of the tests from Epigenomics and Exact Sciences online, ahead of a two-day meeting that starts Wednesday.

Doctors have long used stool tests to look for hidden blood that can be a warning sign of tumors and .

Both tests reviewed by the FDA were more accurate at detecting tumors and worrisome growths than the traditional blood stool test. However, both tests also returned more false positives—reporting growths when none were actually present.

Explore further: New test offers greater accuracy in early detection of colorectal cancer

Related Stories

New test offers greater accuracy in early detection of colorectal cancer

January 19, 2012
Results of two studies suggest that a new, investigational colorectal cancer screening test developed in a collaboration between Mayo Clinic and Exact Sciences Inc. of Madison, Wis., is highly accurate and significantly more ...

Study: Colonoscopy cuts colon cancer death risk

February 22, 2012
(AP) -- Millions of people have endured a colonoscopy, believing the dreaded exam may help keep them from dying of colon cancer. For the first time, a major study offers clear evidence that it does.

Mailing free tests to patients' homes boosts colon cancer screening rates

February 26, 2014
Colon cancer screening rates increased by nearly 40 percent when free stool tests were mailed to patients' homes, according to results of a pilot study published today in the journal BMC Cancer.

Noninvasive colorectal cancer screening tool shows unprecedented detection rates

March 19, 2014
Results of a clinical trial of Cologuard show unprecedented rates of precancer and cancer detection by a noninvasive test. The detection rates are similar to those reported for colonoscopy. The results were published in the ...

Colon cancer screening: Immunological tests are superior

May 28, 2013
Tests for hidden traces of blood ("occult blood") in the stool provide clues to colon cancer or precancerous lesions. For over 40 years, an enzymatic detection method has been used to detect the diseases. Now immunological ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.